Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
about
Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Predicting outcomes of prostate cancer immunotherapy by personalized mathematical modelsLestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib.PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells.Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma.Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer.
P2860
Q30313903-1204EABB-60FC-4334-B7EF-3999548312D9Q33769175-AC8B35DC-16E2-4A0F-BC40-FD461F0E993FQ34097586-7C6291C4-C031-4C83-8B41-3881B3CDA462Q35833152-A170CC4E-8725-476E-AE3B-B13D3D920314Q38928703-321C0331-0AB1-40D1-B586-5AE304146807Q39806462-9E7DE003-A958-45F7-93DD-71B42E6F0F10Q41231657-41663192-4BC9-4620-B67B-8CD7145BDA55
P2860
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Preclinical and clinical studi ...... esponse as a primary endpoint.
@ast
Preclinical and clinical studi ...... esponse as a primary endpoint.
@en
Preclinical and clinical studi ...... esponse as a primary endpoint.
@nl
type
label
Preclinical and clinical studi ...... esponse as a primary endpoint.
@ast
Preclinical and clinical studi ...... esponse as a primary endpoint.
@en
Preclinical and clinical studi ...... esponse as a primary endpoint.
@nl
prefLabel
Preclinical and clinical studi ...... esponse as a primary endpoint.
@ast
Preclinical and clinical studi ...... esponse as a primary endpoint.
@en
Preclinical and clinical studi ...... esponse as a primary endpoint.
@nl
P2093
P2860
P356
P1476
Preclinical and clinical studi ...... esponse as a primary endpoint.
@en
P2093
Connie Collins
Janet S Walczak
John T Isaacs
Mario A Eisenberger
Michael A Carducci
Roberto Pili
Samuel R Denmeade
Victoria J Sinibaldi
P2860
P304
P356
10.4161/CBT.6.9.4541
P577
2007-06-05T00:00:00Z